There are many drugs available for men that increase their sexual libido, but there was none for women. But now, that thing is of past, as on Tuesday, US health regulators have approved the first such drug for women to treat low sexual desire. The approval has come with a warning that it could cause low blood pressure, fainting is also possible and chances increase when taken with alcohol.

The pink-colored pill developed by Sprout Pharmaceuticals will be sold under the brand name Addyi. Owing to safety issues, the drug will only be available through certified and specially trained health care professionals and pharmacies.

Addyi’s chemical name is flibanserin, which has been designed for premenopausal women who does not feel enough sexual desire. The condition is known as hypoactive sexual desire disorder (HSDD). The drug needs to be taken on regular basis.

Before giving a go-ahead this time, the FDA has rejected the approval of the drugs twice over concerns that its benefits do not outweigh its risks. But then, the agency came under pressure from advocacy groups who said that women are being unfairly denied access to the therapy.

Len Yaffe, managing director of healthcare hedge fund Kessef Capital Management, was of the view that the drug’s side effects and little efficacy could become a hurdle from reaching its annual sales to $300 million.